Abstract: Disclosed are a sound generator and an audio device. The sound generator includes a magnetically conductive plate, a first magnetic structure, a second magnetic structure, a treble diaphragm, a treble voice coil, a bass diaphragm and a bass voice coil. The first magnetic structure includes a first washer including a first sub-washer located and a second sub-washer provided surrounding the first sub-washer, and a treble magnetic gap is formed between the first sub-washer and the second sub-washer. A bass magnetic gap is formed between the first magnetic structure and the second magnetic structure. The treble voice coil is provided on a side of the treble diaphragm close to the magnetically conductive plate and is provided corresponding to the treble magnetic gap. The bass voice coil is provided on a side of the bass diaphragm close to the magnetically conductive plate and is provided corresponding to the bass magnetic gap.

Abstract: An acoustic device comprises a sound generating unit having a vibration diaphragm, the acoustic device is provided with a sound outlet, the sound waves at a front side of the vibration diaphragm radiates to the outside through the sound outlet; and an enclosed closed cavity formed at a rear side of the vibration diaphragm, the closed cavity is divided into first and second closed cavities by a partition part, and at least a portion of the partition part flexibly deforms, the first closed cavity is adjacent to the vibration diaphragm, the second closed cavity is far away from the vibration diaphragm, the volume of the second closed cavity is larger than that of the first closed cavity; the second closed cavity encloses the sound waves into the second closed cavity; at least a part of an electronic apparatus housing is used for forming the first and/or the second closed cavity.

Abstract: The present disclosure provides a sound generating unit, a sound generating module and electronic terminal, comprising a magnetic circuit system, a vibration system, and a circuit board. The voice coil is jointly wound by two voice coil wires, and the two end portions of each voice coil wire respectively form a wire-in end and a wire-out end; the lead-out positions of the two wire-in ends are located on one side of the voice coil, and the lead-out positions of the two wire-out ends are located on the other side of the voice coil; the two wire-in ends and the two wire-out ends are electrically connected to the corresponding pads of the circuit board respectively, and the internal circuit of the circuit board is configured to electrically connect the two wire-in ends together, and electrically connect the two wire-out ends together.

Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.

Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.

Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.

Abstract: A globally unique transaction identifier for each transaction is recorded in log entries pursuant to a two-phase commit protocol, wherein multiple log entries in multiple database recovery logs that correspond to one transaction have a same globally unique transaction identifier. A causally ordered, ascending timestamp value is maintained in the log entries pursuant to the two-phase commit protocol. For each of the multiple database recovery logs, all the log entries related to a single transaction are marked identically with a mark unique to the single transaction in a given one of the database recovery logs. Global changes are identified for the single transaction from the log entries in the multiple database recovery logs based on the marking and the globally unique transaction identifier for each transaction by reading log entries based on the causally ordered, ascending timestamp value.

Abstract: Provided are a method, system, and program for merging independent log entries in a multiple node shared nothing DBMS. Initially, log entries from multiple log entries are combined to form a single log entry sequence. Local transactions are generated from the single log entry sequence and stored in a local transactions structure. In particular, log entries with the same local transaction identifier form a local transaction. Then, local transactions having the same global identifier are merged to form global transactions.

Abstract: Provided are a method, system, and program for merging independent log entries in a multiple node shared nothing DBMS. Initially, log entries from multiple log entries are combined to form a single log entry sequence. Local transactions are generated from the single log entry sequence and stored in a local transactions structure. In particular, log entries with the same local transaction identifier form a local transaction. Then, local transactions having the same global identifier are merged to form global transactions.